Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment

Dow Jones

2025/05/02

By Stephen Nakrosis

Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials.

The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials.

Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said.

Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency.

The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

May 01, 2025 17:45 ET (21:45 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2532783943"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2532783943\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2532783943?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-02 05:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2532783943","market":"other","top_or_hot":-1,"title":"Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. \n</p>\n<p>\n  The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials. \n</p>\n<p>\n  Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said. \n</p>\n<p>\n  Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency. \n</p>\n<p>\n  The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2025 17:45 ET (21:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPliant Therapeutics Reduces Workforce as Part of Strategic Realignment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-05-02 05:45</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  Pliant <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. \n</p>\n<p>\n  The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials. \n</p>\n<p>\n  Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said. \n</p>\n<p>\n  Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency. \n</p>\n<p>\n  The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 01, 2025 17:45 ET (21:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2532783943","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2532783943","pubTimestamp":1746135900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials.The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials.Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said.Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency.The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","PLRX":"Pliant Therapeutics, Inc.","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"作为战略调整的一部分，Pliant Therapeutics裁员","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PLRX":0.9,"LENZ":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  Pliant Therapeutics said it would reduce its current workforce by about 45%, part of a strategic realignment to position the company for execution of late stage clinical trials. \n\n\n  The company said Thursday its strategic restructuring and other cost-saving actions will extend its cash runway to support execution of late stage clinical trials. \n\n\n  Pliant is currently waiting for topline data from the BEACON-IPF Phase 2b/3 trial of bexotegrast to patients with idiopathic pulmonary fibrosis, a respiratory system illness. Once available, the company will evaluate the final dataset and determine next steps for bexotegrast's development, it said. \n\n\n  Bexotegrast has received fast track designation from the Food and Drug Administration and orphan drug designation from the FDA and the European Medicines Agency. \n\n\n  The restructuring will impact all departments, and the process is expected to be substantially completed by the end of the second quarter, Pliant said. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 01, 2025 17:45 ET (21:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}